Your search for non small cell lung cancer returned 14 results

Your search for non small cell lung cancer returned 14 results

Sort Results:

Relevant Recent

News

Libtayo Plus Chemotherapy Approved as First-Line Treatment for Advanced NSCLC

Publish Date November 9, 2022

Findings showed that treatment with cemiplimab-rwlc plus platinum-based chemotherapy demonstrated a statistically significant improvement in overall survival.

News

Keytruda Approved as Adjuvant Treatment for Stage IB, II, or IIIA NSCLC

Publish Date January 27, 2023

The approval was based on data from the KEYNOTE-091 trial.

News

Imjudo Plus Imfinzi and Chemotherapy Approved for Metastatic NSCLC

Publish Date November 11, 2022

The approval was based on data from a phase 3 POSEIDON study.

Drugs in the Pipeline

FDA Passes on Poziotinib for HER2 Exon 20 Insertion Mutation Positive NSCLC

Publish Date November 28, 2022

According to the CRL, the application could not be approved in its present form as additional data, including a randomized controlled trial, would be required.

News

Krazati Approved for KRASG12C-Mutated Locally Advanced or Metastatic NSCLC

Publish Date December 13, 2022

Krazati is a highly selective and potent oral small molecule inhibitor of KRASG12C.

News

Enhertu Gets Accelerated Approval for HER2-Mutant Metastatic NSCLC

Publish Date August 12, 2022

The accelerated approval was based on data from the phase 2 DESTINY-Lung02 trial that included adults with HER2-mutant metastatic NSCLC after 1 prior systemic therapy.

News

Tabrecta Granted Full Approval for Metastatic NSCLC Based on Confirmatory Data

Publish Date August 12, 2022

The full approval was based on data from an additional 63 adults with metastatic NSCLC with confirmed MET exon 14 skipping as well as 22 months of follow-up time.

News

Ready-to-Dilute Pemfexy Gains Additional NSCLC Indication

Publish Date December 19, 2022

The ready-to-dilute formulation was developed to eliminate the reconstitution step with Alimta.

News

Bevacizumab Biosimilar Alymsys Now Available

Publish Date October 4, 2022

Alymsys is a vascular endothelial growth factor inhibitor.

News

NSCLC Survival Improved With FDG PET/CT Imaging Before Radiation Therapy

Publish Date February 6, 2023

Despite NCCN guidelines recommending FDG PET/CT, 43.6 percent of patients were imaged with CT alone before subsequent radiation therapy